Clinical Trial Detail

NCT ID NCT02346955
Title Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements no
Sponsors Merck Sharp & Dohme Corp.
Indications

non-small cell lung carcinoma

melanoma

urinary bladder cancer

ovarian cancer

skin melanoma

colorectal cancer

stomach cancer

Therapies

CM-24

CM-24 + Pembrolizumab

Age Groups: adult

No variant requirements are available.